Trial Profile
A 6-week randomized, double-blind, placebo-controlled, crossover study to assess the effect of fluticasone 250microg/salmeterol 50microg combination (FSC 250/50) on exertional dyspnea in patients with symptomatic mild COPD [chronic obstructive pulmonary disease].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Chronic obstructive pulmonary disease; Dyspnoea
- Focus Therapeutic Use
- 14 Apr 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 14 Apr 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
- 14 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.